Latest Healthcare News

Algorae Pharmaceuticals has advanced its AI-driven drug discovery platform into preclinical validation through a strategic collaboration with the Peter MacCallum Cancer Centre, while progressing its therapeutic pipeline and commercial leadership.

EMVision Medical Devices has secured ethics approvals for two pivotal clinical studies and received a $400,000 milestone payment, marking significant progress toward commercialising its portable First Responder brain scanner.

Mach7 Technologies closes FY25 with solid recurring revenue growth, positive cash flow, and a refreshed leadership team focused on innovation and customer value.

Bioxyne Limited has reported record revenue and cash flow for FY25, driven by robust growth in the Australian medical cannabis market and strategic advances into Europe and the UK.

Emyria has inked a pivotal agreement with Avive Health to launch its first Empax clinic in Queensland, expanding its innovative mental health treatment network. This move builds on its recent Medibank partnership, advancing accessible, reimbursed care for treatment-resistant conditions.

Epsilon Healthcare has emerged from voluntary administration with a stronger balance sheet, securing refinancing and preparing to launch its new pharmacy platform. Operational stability and strategic initiatives signal a turning point for the healthcare group.

TruScreen Group Limited has announced a placement of over 1.7 million shares to settle marketing invoices and provide an equity incentive to its CFO, signaling strategic capital management ahead of its next growth phase.

Anatara Lifesciences has received nearly $1 million from the Australian Government’s R&D tax incentive, providing a vital capital injection to advance its Anti-Obesity pre-clinical studies.

PainChek Limited has raised A$7.5 million through a strongly supported placement to accelerate its US market entry following anticipated FDA clearance and expand its innovative AI pain assessment technology internationally.

Compumedics has secured two significant four-year distribution agreements in China worth A$24.4 million, reinforcing its strategic foothold in Asia with committed annual growth of at least 10%.

Emyria has secured a landmark multi-year funding agreement with Medibank to reimburse PTSD patients under its Empax program, alongside opening a second clinic and reporting durable clinical improvements in treatment-resistant PTSD cases.

Clarity Pharmaceuticals has completed a $203 million institutional placement at a premium, bolstering its cash reserves to nearly $288 million and positioning the company to advance pivotal clinical trials and commercial preparations for its cancer-fighting radiopharmaceuticals.